• Skip to primary navigation
  • Skip to main content
  • Skip to footer
AKRN

AKRN

Scientific Consulting

  • Services
    • Clinical Services
    • Regulatory Services
    • Quality Management Services
    • Medical Writing
    • Clinical Data Management
    • Statistical Analysis and Reporting
    • Medical Aesthetic Devices
    • COVID-19
  • Team
    • Who we are
    • Our team
    • Code of Ethics
    • Our history
    • Our Community
  • News
    • News
    • Resources
    • Social Network
  • Career Portal
  • Contact
  • English
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Clinical Performance Study applications for IVDs in Spain

September 8, 2022 by AKRN

In vitro diagnostic medical devices (IVDs) are increasingly in demand as the medical technology evolves by leaps and bounds. With the application of the In Vitro Diagnostic Medical Device Regulation (EU) 2017/746 (IVDR) on 26th May 2022, the number of Clinical Performance Studies (CPS) has risen as it allows manufacturers to gather sufficient clinical evidence to meet the regulation’s requirements. Our experts highly recommend that IVD manufacturers carefully plan their CPS activities to avoid delaying their product´s access to the European market.

The present article aims to provide manufacturers with an overview of the Ethics Committee (EC) and National Competent Authorities (NCA) application timelines and requirements in the context of an IVD Clinical Performance Study in Spain, Europe.

IVDR CPS application requirements

A gripping aspect of the IVDR is that each Member State can determine the appropriate authority to assess the CPS application or  receive the CPS notification, according to article 67 of the IVDR. Moreover, CPS are subject to scientific and ethical review, the latter of which has to be done by an EC in accordance with national law. The regulation specifies that CPS may only be conducted if an EC has not issued a negative opinion on the study.

Particularly in Spain, NCA approval is only required for interventional studies and those that require surgically invasive sampling or additionally invasive procedures for the purpose of the CPS, according to Article 58 of the regulation. According to the AEMPS, non-interventional studies with IVDs bearing CE-mark will need to be notified to the NCA if one of the following scenarios are present: 1) they involve invasive or burdensome procedures, or 2) they involve diagnostic tests for therapeutic screening that use leftover specimens. On the other hand, EC approval is mandatory for most CPS, regardless of whether them being interventional or not. Their list of requirements is very reasonable, and their path to approval usually requires one round of comments.

Other key considerations for CPS

In addition to the IVDR, manufacturers of IVD planning a CPS should consider ISO 20916:2019. This standard summarizes the good study practice and requirements for conducting a CPS to assess the clinical performance and safety of an IVD, including an overview of the documentation required.

Importantly, ISO 20916 provides further clarification on the differences between non-interventional vs interventional studies, and contains specific guidance to start and conduct a scientifically sound investigation according to the level of risk of the study. It is relevant to highlight that “higher risk” studies are more strictly regulated and therefore, require additional planning time. In contrast, authorities may waive several of the most basic documents we usually find in medical device studies for some non-interventional studies, such as the Informed Consent Form and Insurance Certificate.

If you are interested in obtaining more information about ISO 20916:2019, consider visiting the following link.

Roadmap overview through a CPS start-up process in Spain

The first step towards conducting a study is developing the CPS essential documents (i.e. the Clinical Performance Study plan and summary Informed Consent Form, if applicable), which roughly takes 3 weeks. Said documents are included in the application package to the applicable EC and/or NCA. Following application, the EC and/or NCA reviews the documents and either approves or requests further clarifications or documentation to support the application. It shall be noted that based on site requirements, additional local EC applications may be needed.

In our experience, the EC approval process of a CPS in Spain takes approximately two months from the moment of application until the EC issues a favourable opinion of the study. Meanwhile, NCAs are still transitioning into the CPS processes introduced by the IVDR, and this translates into less clear timelines.  

Another relevant milestone in the start-up phase of CPS’ together with NCA/EC applications is the Clinical Trial Agreement (CTA) execution. The CTA is critical for conducting the study and involves several rounds of negotiation between the legal departments of the study site and the Sponsor. This thorough process usually takes two months, or even more! Nevertheless, negotiations can be performed in parallel with the application phase to shorten the timelines in the attempt of obtaining the fully executed CTA by the time the study is approved.

How can AKRN support manufacturers and clients?

AKRN’s clinical team has thorough expertise in designing, conducting, recording and reporting clinical performance studies. Our team specialises in:

  • Design and conduct of both interventional and non-interventional clinical performance studies across Europe
  • Project management
  • Essential documents development
  • Application package preparation and regulatory applications to Ethics Committee and National Competent Authorities
  • Selection and qualification of sites, and contact with key opinion leaders
  • Design of Case Report Forms and Electronic Data Capture platforms programming
  • Clinical Performance Studies monitoring and site management
  • Data management
  • Biostatistics, including sample size calculation
  • Medical writing: Data Management Plan, Statistical Analysis Plan and Clinical study report

Subject Matter Experts

Ruben Ruiz, M.Sc.
Clinical Affairs Manager
LinkedIn

Lucía García, M.Sc. Associate Manager Clinical Studies & IVD team lead
LinkedIn

Share this article

Category iconCE Mark,  Clinical Investigation,  Clinical Trial,  In vitro diagnostic devices,  IVD,  IVDD,  IVDR,  rapid test Tag iconapplication requirements,  clinical performance studies,  In vitro diagnostic device,  In vitro diagnostics medical devices (IVDs),  IVD medical devices,  Spain

Request a free consultation

Our team will help you to find the best solution for your needs. Our medical device experience and clinical knowledge can help you plan, set up, and execute a clinical trial, or performance study, in an optimal way.

Footer

AKRN Spain

AKRN Scientific Consulting S.L.
Address: Calle de Fuerteventura 4 (office 1.8)
Office Park La Marina
Postal Code: ES-28703 Madrid
Phone: +34 910 25 81 40
VAT ID: ES-B87990925

Contact details

Contact email: contact@akrnconsulting.com
Office phone: +34 910 258 140
Office phone: +34 919 333 814
Go to contact

Content

  • Medical Device Consulting Services
  • Clinical Studies for Medical Devices
  • Medical Writing
  • Regulatory Services
  • Contact

Resources

  • Articles
  • Resources
  • Career Portal

Latest articles

  • Artificial Intelligence challenges in Medical Devices
  • What is good clinical practice (GCP)?
  • Drug or Device? Summary and analysis of MDCG 2022-05 on borderline products
  • TRANSITIONAL PROVISIONS according to (EU) 2017/746 ARTICLE 110 IVDR, AN UPDATE WITH MDCGs published in 2022.
  • FELLOW PROGRAM – THE TALENT INCUBATOR OF A CRO
  • AUDITING A QMS ACCORDING TO ISO 13485

AKRN, Now part of NAMSA, is now ISO 9001:2015 quality certified by EQA, a recognized Spanish accredited certification body. The ISO 9001 standard, established by the International Organization for Standardization (ISO), is the quality standard par excellence, and its structure forms the basis for other quality standards such as the medical device quality standard ISO 13485. Implementing ISO 9001:2015 aims to support organizations in enhancing their overall performance and client satisfaction.

AKRN Scientific Consulting S.L ha sido beneficiaria del Fondo Europeo de Desarrollo Regional cuyo objetivo es mejorar la competitividad de las Pymes y gracias al cual ha puesto en marcha un Plan de Marketing Digital Internacional con el objetivo de mejorar su posicionamiento online en mercados exteriores durante el año 2020. Para ello ha contado con el apoyo del Programa XPANDE DIGITAL de la Cámara de Comercio de Burgos.
“Una manera de hacer Europa”

AKRN Scientific Consulting S.L ha sido beneficiaria de la subvención de contratos de trabajo de la Comunidad de Madrid, cofinanciado por el Fondo Social Europeo y la Iniciativa de Empleo Juvenil, en el marco del Programa Operativo de Empleo Juvenil 2014-2020, gestionado por la Consejería de Economía, Empleo y Hacienda.

La empresa (AKRN Scientific Consulting S.L.) es beneficiaria del Programa “la Caixa” Empleo Joven de ayudas para el fomento de la contratación de personas jóvenes. Estas ayudas están cofinanciadas por el Programa Operativo de Empleo Juvenil / Iniciativa de Empleo Juvenil – Fondo Social Europeo y por la Fundación Bancaria “la Caixa”.

 

 

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Privacy policy – Cookie Policy – Legal Notice –  Copyright © 2023. All rights reserved. Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
AKRN

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy